314 related articles for article (PubMed ID: 22673590)
1. Avastin saga reveals debate over clinical trial endpoints.
Sharma SP
J Natl Cancer Inst; 2012 Jun; 104(11):800-1. PubMed ID: 22673590
[No Abstract] [Full Text] [Related]
2. Avastin hearing leads to more uncertainty over drug's future.
Goozner M
J Natl Cancer Inst; 2011 Aug; 103(15):1148-50. PubMed ID: 21768534
[No Abstract] [Full Text] [Related]
3. Avastin withdrawal symptoms.
Lynce F; Swain SM
Expert Opin Pharmacother; 2012 Feb; 13(3):293-8. PubMed ID: 22263961
[No Abstract] [Full Text] [Related]
4. Avastin for breast cancer, 2005-2011: requiescat in pacem?
Burstein HJ
J Natl Compr Canc Netw; 2011 Dec; 9(12):1321-3. PubMed ID: 22157551
[No Abstract] [Full Text] [Related]
5. FDA panel votes to pull Avastin in breast cancer, again.
Ratner M
Nat Biotechnol; 2011 Aug; 29(8):676. PubMed ID: 21822226
[No Abstract] [Full Text] [Related]
6. Changing end points in breast-cancer drug approval--the Avastin story.
D'Agostino RB
N Engl J Med; 2011 Jul; 365(2):e2. PubMed ID: 21707384
[No Abstract] [Full Text] [Related]
7. FDA pulls approval for avastin in breast cancer.
Rose S
Cancer Discov; 2011 Dec; 1(7):OF1-2. PubMed ID: 22586694
[TBL] [Abstract][Full Text] [Related]
8. Avastin's uncertain future in breast cancer treatment.
Twombly R
J Natl Cancer Inst; 2011 Mar; 103(6):458-60. PubMed ID: 21393607
[No Abstract] [Full Text] [Related]
9. Pushing the envelope.
Nat Biotechnol; 2011 Aug; 29(8):669. PubMed ID: 21822220
[No Abstract] [Full Text] [Related]
10. Position paper: the need for head-to-head studies comparing Avastin versus Lucentis.
Schmucker C; Antes G; Lelgemann M
Surv Ophthalmol; 2009; 54(6):705-7. PubMed ID: 19818262
[No Abstract] [Full Text] [Related]
11. FDA. Once on 'fast track,' avastin now derailed.
Couzin-Frankel J; Ogale Y
Science; 2011 Jul; 333(6039):143-4. PubMed ID: 21737712
[No Abstract] [Full Text] [Related]
12. Ovarian cancer treatments on the horizon.
Schmidt C
J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
[No Abstract] [Full Text] [Related]
13. [Strategies of breast cancer treatment based on determination of biological subtype].
Semiglazov VF
Vopr Onkol; 2011; 57(5):542-52. PubMed ID: 22238922
[No Abstract] [Full Text] [Related]
14. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Model for Testing Emerging Targeted Therapies in Breast Cancer.
Esposito A; Criscitiello C; Curigliano G
J Natl Cancer Inst Monogr; 2015 May; 2015(51):51-5. PubMed ID: 26063887
[TBL] [Abstract][Full Text] [Related]
16. FDA cancels approval for bevacizumab in advanced breast cancer.
Tanne JH
BMJ; 2011 Nov; 343():d7684. PubMed ID: 22121166
[No Abstract] [Full Text] [Related]
17. Reputation and precedent in the bevacizumab decision.
Carpenter D; Kesselheim AS; Joffe S
N Engl J Med; 2011 Jul; 365(2):e3. PubMed ID: 21707383
[No Abstract] [Full Text] [Related]
18. [Metastatic colorectal carcinoma: bevacizumab extends total survival].
Pflege Z; 2013 Apr; 66(4):252. PubMed ID: 23634556
[No Abstract] [Full Text] [Related]
19. Bevacizumab recommendation highlights difficulties.
Printz C
Cancer; 2011 Nov; 117(22):5025. PubMed ID: 22052367
[No Abstract] [Full Text] [Related]
20. Progress against solid tumors in danger: the metastatic breast cancer example.
Cortés J; Calvo E; González-Martín A; Dawood S; Llombart-Cussac A; De Mattos-Arruda L; Gómez P; Silva O; Perez EA; Rugo HS; Lluch A; Hortobagyi GN
J Clin Oncol; 2012 Oct; 30(28):3444-7. PubMed ID: 22927522
[No Abstract] [Full Text] [Related]
[Next] [New Search]
